Boston's spinal cord stimulation leads approved by FDA
This article was originally published in Clinica
The US FDA has granted premarket approval (PMA) for two of Boston Scientific's spinal cord stimulation leads, the Linear 3-4 and Linear 3-6. The leads are intended for use with the firm's Precision Plus spinal cord stimulator system, for the treatment of chronic pain of the trunk and/or limbs. The leads deliver electrical pulses from an implantable generator to the spinal cord – these are thought to mask pain signals to the brain. Natick, Massachusetts-based Boston plans to launch the devices in the US immediately; they are already available in Europe. The company claims it now has the "broadest range of percutaneous lead configurations in the industry".
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.